Rituximab improves survival in mantle cell lymphoma

被引：0
|
作者：
不详
机构：
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2012年 / 73卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [31] Is rituximab effective as a single agent in mantle-cell lymphoma?
    Grillo-López, AJ
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (10): : 500 - 501
  • [32] Is rituximab effective as a single agent in mantle-cell lymphoma?
    Antonio J Grillo-López
    Nature Clinical Practice Oncology, 2005, 2 : 500 - 501
  • [33] Rituximab maintenance for mantle cell lymphoma: A meta-analysis.
    Hilal, Talal
    Wang, Zhen
    Almader-Douglas, Diana
    Rosenthal, Allison Claire
    Reeder, Craig B.
    Jain, Tania
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] INCIDENCE AND SURVIVAL TRENDS IN MANTLE CELL LYMPHOMA
    Epperla, N.
    Hamadani, M.
    Fenske, T. S.
    Costa, L. J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (04) : 834 - 834
  • [35] Incidence and survival trends in mantle cell lymphoma
    Epperla, Narendranath
    Hamadani, Mehdi
    Fenske, Timothy S.
    Costa, Luciano J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (05) : 703 - 706
  • [36] Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
    Rusconi, Chiara
    Cheah, Chan Y.
    Eyre, Toby A.
    Tucker, David
    Klener, Pavel
    Gine, Eva
    Crucitti, Lara
    Muzi, Cristina
    Iadecola, Sara
    Infante, Gabriele
    Bernard, Sophie
    Auer, Rebecca L.
    Pagani, Chiara
    Duglosz-Danecka, Monika
    Mocikova, Heidi
    van Meerten, Tom
    Cencini, Emanuele
    Marin-Niebla, Ana
    Williams, Michael E.
    Angelillo, Piera
    Nicoli, Paolo
    Arcari, Annalisa
    Morello, Lucia
    Mannina, Donato
    Vitagliano, Orsola
    Sartori, Roberto
    Chiappella, Annalisa
    Sciarra, Roberta
    Stefani, Piero M.
    Dreyling, Martin
    Seymour, John F.
    Visco, Carlo
    BLOOD, 2022, 140 (17) : 1907 - 1916
  • [37] Addition of rituximab to TBI/CY improves the outcome of first-line autologous stem cell transplantation for mantle cell lymphoma
    Seyfarth, B
    Boehme, V
    Stuhlmann, R
    Sonnen, R
    Kneba, M
    Schmitz, N
    Dreger, P
    BONE MARROW TRANSPLANTATION, 2004, 33 : S6 - S6
  • [38] Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine plus Rituximab without Autologous Transplant
    Hill, Brian T.
    Switchenko, Jeffrey M.
    Martin, Peter
    Churnetski, Michael C.
    Sawalha, Yazeed
    Goyal, Subir
    Shanmugasundaram, Krithika
    Calzada, Oscar
    Kolla, Bhaskar
    Bachanova, Veronika
    Gerson, James N.
    Barta, Stefan K.
    Gordon, Max J.
    Danilov, Alexey
    Grover, Natalie S.
    Mathews, Stephanie
    Burkart, Madelyn
    Karmali, Reem
    Ghosh, Nilanjan
    Park, Steven I.
    Epperla, Narendranath
    Bond, David A.
    Badar, Talha
    Blum, Kristie A.
    Guo, Jin
    Hamadani, Mehdi
    Fenske, Timothy S.
    Malecek, Mary-Kate
    Kahl, Brad S.
    Flowers, Christopher R.
    Cohen, Jonathon B.
    BLOOD, 2019, 134
  • [39] Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma
    Nastoupil, Loretta
    Shenoy, Pareen J.
    Ambinder, Alex
    Seward, Miray
    Nooka, Ajay K.
    Waller, Edmund K.
    Langston, Amelia
    Kaufman, Jonathan L.
    King, Nassoma
    Lechowicz, Mary Jo
    Lonial, Sagar
    Sinha, Rajni
    Flowers, Christopher R.
    BLOOD, 2012, 120 (21)
  • [40] Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
    Andrea Borgerding
    Justin Hasenkamp
    Bertram Glaß
    Gerald Wulf
    Lorenz Trümper
    Annals of Hematology, 2010, 89 : 283 - 289
12345